Summary
Medtronic plc (MDT) has filed a Form 8-K detailing its first quarter fiscal year 2026 financial results, announced via press release on August 19, 2025. While the specific financial figures are not detailed within this 8-K filing itself but rather in the furnished press release (Exhibit 99.1), this report signals the company's performance update for the period ending August 2025. Investors should refer to the separate earnings release for critical financial metrics such as revenue, earnings per share, and segment performance. In addition to the financial update, the company announced a significant change to its Board of Directors. Effective August 19, 2025, the Board's size has been expanded from 11 to 13 members with the appointment of two new directors, John Groetelaars and William Jellison. Both new directors will receive standard non-employee director compensation, including cash retainers and equity grants, as per the company's policy. Mr. Jellison has been appointed to newly formed Growth and Operations committees, while Mr. Groetelaars will serve on the Growth committee. These board changes, announced via a separate press release (Exhibit 99.2), aim to bolster the board's oversight and strategic direction.
Key Highlights
- 1Medtronic announced its first quarter fiscal year 2026 financial results via press release on August 19, 2025 (Exhibit 99.1).
- 2The company expanded its Board of Directors from 11 to 13 members.
- 3John Groetelaars and William Jellison were appointed as new directors, effective August 19, 2025.
- 4Mr. Jellison has been appointed to the new Growth and Operations committees.
- 5Mr. Groetelaars has been appointed to the new Growth committee.
- 6New directors will receive standard compensation, including cash retainers and equity grants.
- 7No reportable related-party transactions were disclosed for the new directors.